SCHEMBL23926494

SCHEMBL23926494

Cc1cnc(C(=O)Nc2nc3ccc(N)cc3s2)cn1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.70
NPC1 O15118 10/20 0.58
RAB9A P51151 10/20 0.58
SMN1; SMN2 Q16637 6/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
GFER P55789 1/20 0.58
HTT P42858 3/20 0.54
OPRK1 P41145 2/20 0.54
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 4/20 0.53
TDP1 Q9NUW8 3/20 0.53
ATM Q13315 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
SCD O00767 1/20 0.52
POLB P06746 3/20 0.52
TP53 P04637 2/20 0.52
USP2 O75604 1/20 0.52
GLA P06280 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31219319 0.91 CLK1 (0.62) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL23926497 0.91 CLK1 (0.62) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL31219382 0.85 MAPT (0.66) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL23926470 0.85 MAPT (0.66) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL23926477 0.84 RAB9A (0.53) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL22130268 0.82 NPC1 (0.71) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL31219253 0.82 NPC1 (0.71) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL25382144 0.82 MAPT (0.53) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL30354877 0.82 MAPT (0.53) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL23926531 0.81 NPC1 (0.61) MAPTNPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
CN-113727972-A Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof 韩国科学技术研究院 2021-11-30 CN disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 MAPT 3633/4885NPC1 1264/4885RAB9A 1131/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT MAPT 3061/4885NPC1 3755/4885RAB9A 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.